Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of Dexmedetomidine on Agitation in Critically Ill TBI Patients
Sponsor: Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Summary
Agitation is a frequent complication following traumatic braing injury in patients admitted to the intensive care unit. This agitation frequently results in the liberal use of rescue drugs such as antipsychotics, sedatives and opiates, which in turn may delay rehabilitation, liberation from mechanical ventilation and emergence from posttraumatic amnesia. Dexmedetomidine may be a better agent given it's light sedative properties. The main objective is to assess the feasibility of conducting a multicenter randomized controlled trial of dexmedetomidine following TBI in the ICU.
Official title: Effects of Dexmedetomidine on Agitation in Critically Ill TBI Patients (DEX-TBI)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2024-10-01
Completion Date
2026-12-01
Last Updated
2024-10-01
Healthy Volunteers
No
Interventions
Dexmedetomidine
DEX 4 mcg/100 ml at a starting dose of 0.6 mcg/kg/hour and increased by 0.2 mcg/kg/hour every 30 minutes up to final dose of 1.4 mcg/kg/hour.
Placebo
NaCl 0.9% 100ml